The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children

Highlights • Results confirmed the claimed role of SCN1A c.3184 A/G polymorphism in epilepsy. • Role of SCN1A c.3184 A/G polymorphism in pharmacoresistance to AEDs • CYP3A5 *3 variants have no contributing effect on pharmacoresistance to AEDs

Saved in:
Bibliographic Details
Published inSeizure (London, England) Vol. 41; pp. 75 - 80
Main Authors Abo El Fotoh, Wafaa Moustafa M, Abd el naby, Sameh abd Allah, El-din Habib, Mona Salah, Ahmed AL-refai, Abeer, Kasemy, Zeinab A
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2016
Subjects
Anticonvulsants - therapeutic use
Child
Child, Preschool
CYP3A53
Cytochrome P-450 CYP3A - genetics
Drug Resistant Epilepsy - genetics
Drug-resistant
Egypt
Epilepsy
Female
Genetic polymorphisms
Genetic Predisposition to Disease - genetics
Genotype
Humans
Male
NAV1.1 Voltage-Gated Sodium Channel - genetics
Neurology
Polymorphism, Single Nucleotide - genetics
SCN1A
Statistics, Nonparametric
genetic polymorphisms
drug-resistant
Epilepsy
CYP3A53
SCN1A
Drug-resistant
Genetic polymorphisms
Online AccessGet full text

Cover

More Information
Summary:Highlights • Results confirmed the claimed role of SCN1A c.3184 A/G polymorphism in epilepsy. • Role of SCN1A c.3184 A/G polymorphism in pharmacoresistance to AEDs • CYP3A5 *3 variants have no contributing effect on pharmacoresistance to AEDs
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1059-1311
1532-2688
DOI:10.1016/j.seizure.2016.07.005